Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -232.42 Thousand USD | -470.4% |
| 2022 | -40.74 Thousand USD | -96.15% |
| 2021 | -20.77 Thousand USD | -40.38% |
| 2020 | -14.79 Thousand USD | 43.31% |
| 2019 | -26.1 Thousand USD | -1617.41% |
| 2018 | -1519.95 USD | 56.47% |
| 2017 | -3491.75 USD | -76.84% |
| 2016 | -1974.51 USD | 53.03% |
| 2015 | -4203.92 USD | -371.28% |
| 2014 | -892.03 USD | 49.51% |
| 2013 | -1766.84 USD | -185.71% |
| 2012 | 2061.50 USD | 278.85% |
| 2011 | -1152.61 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -2.28 USD | -8251.65% |
| 2024 Q2 | -1.47 USD | 35.53% |
| 2023 Q3 | -53.74 USD | 66.22% |
| 2023 FY | - USD | -470.4% |
| 2023 Q1 | -46.64 USD | 98.63% |
| 2023 Q2 | -159.09 USD | -241.1% |
| 2023 Q4 | -0.03 USD | 99.95% |
| 2022 Q2 | -36.24 Thousand USD | -453.88% |
| 2022 Q1 | -6543.64 USD | -3.52% |
| 2022 FY | - USD | -96.15% |
| 2022 Q4 | -3409.76 USD | 32.93% |
| 2022 Q3 | -5083.91 USD | 85.97% |
| 2021 FY | - USD | -40.38% |
| 2021 Q2 | -5198.06 USD | 5.12% |
| 2021 Q4 | -6321.06 USD | -63.35% |
| 2021 Q3 | -3869.56 USD | 25.56% |
| 2021 Q1 | -5478.39 USD | -4906.3% |
| 2020 Q2 | -74.69 USD | 77.04% |
| 2020 Q4 | -109.43 USD | 56.95% |
| 2020 Q3 | -254.22 USD | -240.37% |
| 2020 Q1 | -325.37 USD | -84.0% |
| 2020 FY | - USD | 43.31% |
| 2019 Q4 | -176.83 USD | 35.55% |
| 2019 Q3 | -274.36 USD | 48.96% |
| 2019 Q2 | -537.51 USD | -43.68% |
| 2019 Q1 | -374.11 USD | -89.75% |
| 2019 FY | - USD | -1617.41% |
| 2018 Q1 | -535.76 USD | 23.46% |
| 2018 FY | - USD | 56.47% |
| 2018 Q4 | -197.16 USD | 10.31% |
| 2018 Q3 | -219.82 USD | 66.31% |
| 2018 Q2 | -652.57 USD | -21.8% |
| 2017 Q4 | -699.94 USD | -75.59% |
| 2017 Q1 | -2076.38 USD | -149.07% |
| 2017 Q2 | -463.45 USD | 77.68% |
| 2017 Q3 | -398.63 USD | 13.99% |
| 2017 FY | - USD | -76.84% |
| 2016 Q4 | -833.64 USD | -106.13% |
| 2016 FY | - USD | 53.03% |
| 2016 Q2 | -389.64 USD | -17.84% |
| 2016 Q3 | -404.42 USD | -3.79% |
| 2016 Q1 | -330.66 USD | -38.43% |
| 2015 Q2 | -751.02 USD | -2.6% |
| 2015 FY | - USD | -371.28% |
| 2015 Q4 | -238.86 USD | 65.93% |
| 2015 Q3 | -701.15 USD | 6.64% |
| 2015 Q1 | -732.02 USD | 91.0% |
| 2014 Q3 | -797.55 USD | -66.97% |
| 2014 FY | - USD | 49.51% |
| 2014 Q2 | -477.67 USD | 48.15% |
| 2014 Q1 | -921.29 USD | -449.3% |
| 2014 Q4 | -8133.33 USD | -919.79% |
| 2013 Q3 | -485.12 USD | -19.28% |
| 2013 Q2 | -406.69 USD | 38.28% |
| 2013 FY | - USD | -185.71% |
| 2013 Q4 | -167.72 USD | 65.43% |
| 2013 Q1 | -658.97 USD | -168.41% |
| 2012 FY | - USD | 278.85% |
| 2012 Q3 | 613.39 USD | -20.16% |
| 2012 Q4 | 963.31 USD | 57.05% |
| 2012 Q1 | -283.42 USD | 0.0% |
| 2012 Q2 | 768.23 USD | 371.06% |
| 2011 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| America Great Health | - USD | Infinity% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | -2178246.298% |
| Aridis Pharmaceuticals, Inc. | -1.64 USD | -14172433.537% |
| Biora Therapeutics, Inc. | -7.87 USD | -2953261.499% |
| Bio-Path Holdings, Inc. | -33.64 USD | -690832.075% |
| Better Therapeutics, Inc. | -1.69 USD | -13753127.811% |
| Calithera Biosciences, Inc. | -7.94 USD | -2927224.307% |
| Comera Life Sciences Holdings, Inc. | -1.76 USD | -13206124.432% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -16.37 USD | -1419750.641% |
| Eloxx Pharmaceuticals, Inc. | -16.65 USD | -1395873.273% |
| Evelo Biosciences, Inc. | -26.28 USD | -884335.122% |
| Evolutionary Genomics, Inc. | -0.35 USD | -66408342.857% |
| Finch Therapeutics Group, Inc. | -46.59 USD | -498782.915% |
| Galera Therapeutics, Inc. | -1.33 USD | -17475806.015% |
| Innovation1 Biotech Inc. | -0.70 USD | -33204121.429% |
| Kiromic BioPharma, Inc. | -21.41 USD | -1085512.097% |
| Molecular Templates, Inc. | -1.80 USD | -12912652.778% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -39394738.983% |
| NexImmune, Inc. | -30.82 USD | -754051.687% |
| Orgenesis Inc. | -1.91 USD | -12168986.387% |
| Point of Care Nano-Technology, Inc. | -0.10 USD | -232429450.0% |
| PaxMedica, Inc. Common Stock | -11.00 USD | -2112895.909% |
| Scopus BioPharma Inc. | -0.55 USD | -42259818.182% |
| Sorrento Therapeutics, Inc. | -1.37 USD | -16965560.584% |
| Statera Biopharma, Inc. | -4.97 USD | -4676550.905% |
| TRACON Pharmaceuticals, Inc. | -2.20 USD | -10564879.545% |
| Trevena, Inc. | -54.51 USD | -426298.0% |
| Vaxxinity, Inc. | -0.45 USD | -51650911.111% |
| Vaccinex, Inc. | -43.68 USD | -532018.933% |
| Vicapsys Life Sciences, Inc. | -0.03 USD | -679618467.251% |
| Viracta Therapeutics, Inc. | -1.32 USD | -17608199.242% |
| ZIVO Bioscience, Inc. | -4.60 USD | -5052716.304% |